Login to Your Account

Next Year; Patients Impatient

FDA: New CFS Draft Guidance Could ‘Catalyze’ Development

By Randy Osborne
Staff Writer

Friday, October 18, 2013
Specific guidance for companies aiming to more quickly develop drugs for chronic fatigue syndrome (CFS) and myalgic encephalomyelitis (ME) will be available next year from the FDA, said Janet Maynard, from the agency’s office of pulmonary, allergy and rheumatology products.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription